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A nation’s health and economic development are inextricably and
synergistically connected. Stark differences exist between wealthy
and developing nations in the use of cardiac implantable electronic
devices (CIEDs). Cardiovascular disease is now the leading cause of
death in low- and middle-income countries (LMIC), with a signiﬁcant burden from rhythm-related diseases. As science, technology,
education, and regulatory frameworks have improved, CIED recycling for exportation and reuse in LMIC has become possible and
primed for widespread adoption. In our manuscript, we outline
the science and regulatory pathways regarding CIED reuse. We propose a pathway to advance this technology that includes creating a
task force to establish standards for CIED reuse, leveraging profes-

A nation’s health and economic development are
inextricably and synergistically connected.1 Stark health
disparities exist between high-income countries and low/
middle-income countries (LMIC), especially in resourceintensive specialties such as clinical cardiac electrophysiology (EP), cardiac implantable electronic device (CIED)
utilization, and ablation of arrhythmias (Figure 1). For
instance, in a high-income nation such as France, 782
pacemaker implants per million are performed annually,
contrasted to 4 per million each year in a low-income country
such as Pakistan.2 Poor global access to CIED therapy is
estimated to account for at least 1 million deaths annually,
as well as orders of magnitude more in physical and
psychological morbidity and stunted economic activity.3,4
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sional organizations in areas of need to foster the professional skills
for CIED reuse, collaborating with regulatory agencies to create
more efﬁcient regulatory expectations and bring the concept to
scale, and establishing a global CIED reuse registry for quality
assurance and future science.
KEYWORDS Pacemaker; Recycling; CIED; Low; Middle income countries
(Heart Rhythm O2 2022;3:799–806) © 2022 Heart Rhythm Society.
Published by Elsevier Inc. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).

As science, education, and technology advance in the
ﬁeld of EP, this progress naturally transcends national
and continental borders, albeit unevenly, with signiﬁcant
access disparities in LMIC. As a larger global EP community, it is our collective responsibility to target these
disparities and identify concepts that may be ready for
widespread adoption. No concept seems better positioned,
tested, and primed for widespread adoption than CIED recycling for exportation and reuse in LMIC. Given the
relative contributions of conduction disease vs sudden cardiac death, our discussion of CIED recycling will focus
on pacing as a ﬁrst step mirroring efforts and data to
date. However, in time many of these concepts may be
applied to broader CIED reuse. In this manuscript, we
will characterize the need, review the evidence, and
describe the regulatory framework around CIED
recycling for export. In our experiences and based on
the literature, the widespread practice of CIED reuse is

2666-5018/© 2022 Heart Rhythm Society. Published by Elsevier Inc. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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KEY FINDINGS
-

Cardiac implantable electronic device (CIED) recycling
has the potential to make a signiﬁcant impact on the
leading cause of mortality in low- and middle-income
countries (LMIC) worldwide.

-

As science, technology, education, and regulatory
framework have improved, CIED recycling for exportation and reuse in LMIC has become possible and primed
for widespread adoption.

-

CIED recycling is medically feasible, is ethical, and will
have a positive economic downstream effect on
developing nations.

hindered by conceptual misunderstanding and delays in
learning to navigate the regulations rather than any
inherent risks of the practice. The scientiﬁc data to support safe CIED reuse already exist and the regulatory requirements are already present, albeit complex. We
believe that the broader EP community should recognize
and address these issues as this concept “comes of
age.” We have assembled broad and global perspectives
to outline a way forward for CIED recycling for exportation to LMIC.

The problem
While global public health efforts are often focused on
communicable diseases such as HIV/AIDS, malaria, and
other tropical diseases, noncommunicable diseases (NCDs)
such as heart and lung disease and cancer now account for
a larger share of global mortality (40.5 million in 2016)
and cause the majority of deaths in LMIC. Cardiovascular
diseases resulted in 17.9 million deaths in LMIC in 20167;
this is more than all reported deaths from the COVID-19
pandemic thus far.7
The burden of premature deaths owing to lack of access to
CIED in cardiovascular diseases is profound, possibly underestimated, and a considerable societal burden in LMIC. In
2007, it was estimated that without a global effort to target
chronic disease, approximately $87 billion in economic
output would be lost from LMIC over a 9-year period.6 In
developed nations, the average cost of implanting a pacemaker in the EP lab has been estimated at approximately
$2700.8 To put this ﬁgure into context, the average annual
gross national income per capita in an LMIC is between
$1045 and $4095.9 Furthermore, in developing countries, patients requiring pacemakers or at risk for sudden cardiac
death are younger than in high-income countries, leading to
signiﬁcant economic burden on their families and society.10,11 In an effort to combat this issue, the World Health
Assembly adopted the World Health Organization’s Action
Plan for the Prevention and Control of NCDs 2013-2020.9
In its plan, the WHO proposes a framework that empowers
people and communities to take multisectorial action toward
universal equitable coverage and innovative evidence-based

strategies to enhance existing health solutions. As the guiding
principles for this program, the WHO adopted approaches
promoting life course, human rights, and equity, as well as international cooperation.
While it is difﬁcult to precisely determine the relative
contribution of a lack of CIED access to the increasing
LMIC mortality statistics owing to cardiovascular diseases,
it is likely signiﬁcant. This is important context as the EP
community advances CIED recycling to maturity. These efforts have the potential to reduce a signiﬁcant portion of
the leading cause of mortality in LMIC. Treating this cause
of preventable premature death and disability may also
have signiﬁcant positive downstream effects on LMIC
economic development.

The history
The concept of pacemaker recycling originated in the
1970s and 1980s when a number of industrialized countries, including Canada, Australia, France, Sweden, and
Norway, embraced pacemaker domestic generator reuse
for domestic health care. Recognizing the potential
economic beneﬁts of such a practice, the North American
Society of Pacing and Electrophysiology (now the Heart
Rhythm Society [HRS]) in 1985 endorsed the concept
of CIED recycling as long as it adhered to a rigorous
process of testing, resterilization, informed consent, data
analytics, and tracking.12 The tide against domestic
CIED reuse began in 1980 when the United States
Food and Drug Administration (FDA) published guidance
against pacemaker reuse, citing concerns about the feasibility of device header resterilization.13 The European
Union followed suit shortly thereafter, barring the
practice.12,14 These regulatory barriers prevented any
mainstream adoption of CIED recycling in the decades
that followed.
In order for the concept of CIED recycling to regain
acceptance, evidence generation and scientiﬁc validation
was necessary. The cumulative scientiﬁc evidence has been
analyzed in 2 large meta-analyses. In 2011, Baman and colleagues15 analyzed the early experience with pacemaker
reuse in a large meta-analysis of studies dating back to
1980 that took place in both high-income and LMIC nations.
Their analysis included 18 trials, 5 with control groups in a
pooled analysis. They identiﬁed a low risk of infection of
1.97% and a low, yet notable risk of device malfunction of
0.68% in recycled devices.15 In 2018, Sinha and colleagues16
performed a meta-analysis of recent trial data for pacemaker
and implantable cardioverter-deﬁbrillator (ICD) reuse,
including cardiac resynchronization therapy devices. The
analysis included 9 observational studies, 5 with control
groups, published between 2009 and 2017. All of the studies
were performed in LMIC using comparable CIED screening
interrogation, resterilization, and repackaging protocols
using ethylene oxide gas. This analysis found that the rates
of infection, device malfunction, and premature battery
depletion were not signiﬁcantly different from controls.16 A
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Figure 1 A comparison of the number of pacemaker implanting institutions per million inhabitants in European Society of Cardiology member countries (A)
and Pan-African Society of Cardiology countries (B) in 2013.5,6

summary of trials included in these meta-analyses is shown in
Table 1.
Most recently, Khairy and colleagues17 published the
data from a multinational controlled prospective registry
study further supporting the safety and efﬁcacy of CIED
reuse. This study analyzed the outcomes of recycled CIEDs

(pacemakers, ICDs, and cardiac resynchronization therapy
pacemakers and ICDs) implanted in LMIC in Latin America
by experienced providers (.5 years’ experience) in comparison to a control group receiving new CIEDs in Canada. The
study was a subset of a larger program that began in 1983
with the creation of a prospective registry in 2003. The results
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Table 1

Summary of trials included in cardiac implantable electronic device reuse meta-analyses

Study

Country

Year of
completion

Balachander
Pescariu et al
Linde et al
Panja et al
Kruse
Kovacs
Cooperman
Mond et al
Amikam et al
Havia et al
Grendahl
Costa et al
Rosengarten et al
Sedney et al
Aren et al
Ferugilo et al
Namboodri et al
Baman et al
Hasan et al
Kantharia et al
Pavri et al
Nava et al
Feng et al
Jama et al
Sosdean et al
Selvaraj et al

India
Romania
Sweden
India
Sweden
Hungary
Israel
Australia
Israel
Sweden/Finland
Norway
Brazil
Canada
Holland
Sweden
Italy
India
Philippines
Nicaragua
India
India
Mexico
China
South Africa
Romania
India

1988
2001
1996
1992
1985
1980
1984
1978
1982
1974
1993
1982
1987
1983
1979
1978
2001
2008
2011
2012
2012
2013
2014
2015
2015
2017

demonstrated a low 2-year infection rate (2.0% vs 1.2% in
controls, P 5 .06) and no difference in device-related
deaths.17

A summary of programs to date
We applaud these programs and view these programs as
foundational for scaling up of CIED reuse. Our source for
this summary is from prior meta-analysis and members of
our writing group who are active in ongoing CIED reuse
efforts. All published programs we reviewed originated
from single centers that are typically large and often have
an academic component. In older studies, more developed
nations were represented but newer data largely reﬂect the
developing world.15 The oldest study originated in Sweden/Finland, where the process has largely been abandoned.
The newest published study is out of a large academic center in Romania with ICDs procured from “Stimubanque,”
an established organization with longitudinal experience
in refurbishing CIEDs.18 Sterilization processes in these
programs were largely consistent, although there appeared
to be some variations: hydrogen peroxide vs alcoholbased sterilization agent, and use of additional biocidal
agents such as iodine, varied.16 Of the trials presented, it
is difﬁcult to ascertain whether these programs tended
more toward proof of concept vs ongoing sustainable programs. It seems a large share of the early programs in the

Number of reused
pacemakers
140
365
100
120
487
28
78
83
132
50
310
22
18
214
19
87
5
12
17
53
106
307
99
63
127
260

Complications related to
device reuse
Length

Infection

Failure

6y
35 6 21 mo
32 6 11 mo
7.5 6 5.6 y

2
6
2
6
1
None
None
1
3
1
14
1
1
1
None
1
None
None
None
None
None
10
3
0
5
0

None
None
1
None
2
None
None
None
None
None
4
2
1
1
None
None
None
None
None
None
None
12
1
1
1
0

5y
22 mo
16 mo
29 mo
31.5 mo
26 mo
14 mo
19.2 mo
4 mo

developed world were halted, as regulatory agencies took
an unfavorable view on the practice of CIED reuse. This
is why increasing awareness and streamlining the regulatory
environment around this practice is critical for scaling up of
the process moving forward.
Robust programs that serve as proof of concept and are
working to build capacity toward more widespread adoption
of this technique include Project My Heart Your Heart
(MHYH) at the University of Michigan (Ann Arbor, MI)
and Heart Beat International out of the United Kingdom.
These 2 programs have now combined their efforts. Heart
Beat International serves as a resource for devices to be reconditioned in Michigan.4 MHYH has been working with
the US FDA to develop a standardized exportation process
that may be adopted by other programs. Additionally,
MHYH has published a standardized sterilization process
that may also be replicated.19 The program is now operating
in 4 countries in a clinical trial and the organizers are working
to add another 8 nations. The program employs a web-based
registry that is easily accessed globally, with approximately
15 ﬁelds of data required for entry. This registry may be
foundational for future global registry efforts, as it is easily
adaptable to accommodate large data sets and many centers.
The critique of MHYH is that its efforts are focused largely
on laying the groundwork to demonstrate feasibility and efﬁcacy. Larger efforts will need to move beyond this “proof of
concept” phase.
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Figure 2 An illustration of the sterilization process in Project My Heart Your Heart (modiﬁed with permission from Journal of American College of Cardiology: Electrophysiology). CIED 5 cardiac implantable electronic device.

Behind the data toward standardized and
adoptable processes
Sources
The largest and most reproducible source of recyclable
CIEDs appears to be from funeral homes and crematories,
which represent the majority of published literature.17,20
Data published by the University of Michigan from a statewide effort with funeral homes revealed 21% of CIEDs
had acceptable longevity, which was deﬁned as 75% of
remaining longevity or 4 years.20
Other possible sources are generators removed prematurely because of infection or system revision in the hospital
and during postmortem examinations.21–23 Use of hospitals
as sources of CIEDs would result in high yields of
well-selected devices. About 50% of devices removed from
patients at the University of Michigan EP laboratory for indications other than elective replacement indicator had the minimum of 75% of longevity or 4 years.20 FDA guidance
issued in response to a number of device advisories in the
early to mid 2000s recommends that explanted devices be
returned to the manufacturer for analysis and product
performance observations. This policy should be reconsidered in the light of alternative means of establishing device
performance, such as remote monitoring and postexplant
interrogation.

assurance of 10-24 while maintaining a high rate of appropriate device function.19 An illustration of this process is
shown in Figure 2.
An important concept to address is a standardized
approach to headers and set screws, which represented the
FDA’s original objection to the concept of CIED recycling.
A published report characterized in detail the process of
screw removal, inspection, discarding of malfunctional or
damaged apparatuses, and rigorous cleaning of those still
acceptable for reuse.17,19 This protocol for reprocessing is
the most data-driven approach and appears to be safe, at a
modest cost per recycled CIED of $75–$100 (US dollars).12
However, a more conservative approach, as practiced in most
of the studies included in the 2 aforementioned metaanalyses, may be to inspect and test all set screws and simply
discard those CIEDs with set screws or grommets demonstrating damage or incomplete cleaning. This was also the
practice in the large prospective registry study performed
by Khairy and colleagues.17
Over the decades-long experience with the CIED sterilization process, ethylene oxide has been the method of choice
for the ﬁnal sterilization procedure. This process should
adhere to ISO-11135—the standard established by the American National Standards Institute, Association for the
Advancement of Medical Instrumentation, and International
Organization for Standardization.25

Sterilization process

Leads and monitoring

The potential for device infection owing to inadequate resterilization techniques seems to be the greatest source of
concern from a regulatory and public acceptance standpoint.
Data from the University of Michigan outlined a rigorous
process that met medical industry standards and achieved a
12-log reduction of inoculated product and a sterility

The procurement of approved pacing leads for scaling up
CIED reuse is crucial, since leads cannot be reused. A number of sources have been described in prior programs, ranging
from manufacturer charitable donations to use of expired
leads. However, growing this concept to scale likely cannot
rely on these methods alone. The authors, many of whom
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are involved in ongoing programs, recommend approaching
a manufacturer to supply leads at cost for CIED reuse programs, a model that has already been successful in existing
smaller programs. Such resources are known to be available
even in many recipient LMIC. For instance, because of previous efforts, many programs in sub-Saharan Africa have access to Medtronic leads and programmers. We recommend
building on existing infrastructure in collaboration with
recipient hospitals with CIED reuse efforts for better procurement of leads and to facilitate longitudinal follow-up based
upon local infrastructure. This will provide for a sustainable
and low-cost resource.
With regard to the device monitoring programs, we
recommend a similar approach in LMIC to modern EP
training programs: the physician must be trained not only
to implant a device hardware but also to troubleshoot and
manage its software longitudinally. All implanting institutions must have access to a device programmer, either as their
own resource or from training institutions. Capacity for implantation must be built in combination with longitudinal
in-person monitoring. This model already exists in MHYH.
Through the HRS and other professional organizations, virtual coaching may also be made available by a group of volunteers, given broader and more seamless application of
video-chat platforms. Remote monitoring is not a technology
ready for this application in LMIC owing to inherent infrastructure issues, although it may be considered as programs
mature.

Ethical considerations
Historically, ethical concerns have been raised about recycled devices and their potential risks. We argue these concerns must be weighed against the ethics of not acting to
prevent the signiﬁcant morbidity and mortality related to
poor CIED access in LMIC. Furthermore, the clinical evidence for CIED reuse demonstrates safety, and thus the
ethical balance is in favor of pursuing this technology.
One might argue that at the present time, withholding this
technology can be viewed as unethical. We propose performing studies to understand the perceptions of CIED reuse
in recipient countries. Our understanding of the ethical
context cannot be complete without better understanding
recipient perceptions. Furthermore, these perceptions are
likely to vary across cultures and nations. Our diverse
writing group includes perspectives from recipient nations
to better represent this critical partnership.26 Based upon
our understanding of the existing data, we propose that
the informed consent process for recipients of CIEDs in
LMIC include language about the resterilized device and
our scientiﬁc understanding that there appears to be no signiﬁcant increase in relative risk compared to a de novo device. While there remain many potential avenues for
further inquiry about the ethics of CIED reuse, it is our general belief that the safety data combined with evidence of
signiﬁcant need in LMIC justify this effort as ethical, and
one that should be widely adopted.
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Regulatory framework
The FDA objects to CIED domestic reuse on the grounds of
infection risk and further classiﬁcation as “an objectionable
practice,” raising “a serious question whether pacemakers
can be properly resterilized following initial implantation.”13
FDA approval of CIEDs for single use in the United States
requires that manufacturers provide bench or clinical testing
to demonstrate a “reasonable assurance of safety and effectiveness” without prior implant, use, refurbishment, recleaning, or resterilization. These recommendations date back to
the year 2000, but the FDA’s domestic reuse policy is not
the basis for CIED reuse for exportation. The FDA has
collaborated with early adoption CIED reuse institutions to
create a more transparent and deﬁned process in a very
important ﬁrst step.
The FDA, in working with organizations advocating
CIED reuse, has outlined a process for legally exporting devices to LMIC, as export of devices falls under a different
regulatory context. This is a very important distinction. In
brief, the process requires that the devices be characterized
as not “contrary to public health, safety” by passing quality
assurance, that they be labeled as “reprocessed not approved
for use in the US,” and that a letter be obtained from an accepting foreign liaison from a recipient country communicating that the devices are being accepted as they do not
conﬂict with the laws of the country and the recipient entity
is aware of the status of the devices in the United States.27
This process has been quite effective, although obtaining
such letters from recipient authorities can prove onerous for
implanting physicians and hospitals.

The way forward
Taken together, the emerging evidence base for CIED reuse,
combined with the evolving regulatory framework around
the practice, positions humanitarian CIED recycling as a
concept primed for a “coming of age.” The global EP community’s perceptions of reuse are favorable, and while concerns regarding risk continue to be expressed, data have not
supported an increase in risk.15–17,28 Similarly, surveys indicate that recycling of CIEDs after death or at the time of
CIED removal are favorably viewed by most CIED “donor”
patients.29 Finally, recently published data indicated that
recipient patients and their family members support the
concept of pacemaker reuse for patients who cannot afford
new devices. The published evidence should change perceptions, and we as a community must now advance the culture
around CIED recycling. Given the burden of cardiovascular
disease in LMIC, and a likely signiﬁcant contribution of conduction system disease in this cohort, the impact from widespread and robust application of this therapy could be
profound. We propose the following next 4 steps:

(1). Creating a task force to establish standards
for CIED reuse
A group of key stakeholders in the global effort to assure high
quality of reprocessed devices would have a sole focus to
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assure maximizing patient safety. Such a taskforce could be
composed of delegates of the HRS and members of global
specialty societies such as Asia Paciﬁc HRS, Latin America
HRS, Africa Heart Rhythm Association, and other relevant
organizations, including national cardiac societies. Funding
for such an effort may come from specialty societies or manufacturer charitable contributions. Establishing consensus
standards for device procurement, cleaning, electrical testing,
resterilization, implantation, and monitoring will be essential
for assuring standardized levels of safety and efﬁcacy.
Centralizing the efforts around scaling this technology will
also reduce duplicative efforts and better steward resources
for individual practitioners and institutions. Currently,
Project MHYH estimates the cost of sterilizing a device at
$65 at a yearly volume of 250 devices a year. This is a
commendable accomplishment, and economies of scale can
further be realized with likely even lower costs as programs
are expanded.

(2). Leverage professional organizations in areas
of need to foster the professional skills for CIED
reuse
Enhancing the infrastructure for providing reused CIEDs to
LMICs must be complemented by a corresponding focus
on building the professional capability for device implantation and follow-up. A model of this concept may be found
in the partnership between Project MHYH and the African
Heart Rhythm Association and Pan-African Society of Cardiology. In recognizing the need for this expertise in Africa, the
Pan-African Society of Cardiology has established a 6-month
device implantation fellowship open to physicians in every
sub-Saharan African country without a pacemaker implantation service, with a goal of addressing this deﬁciency by
2030.30,31 Future efforts must build on this model so that
areas of need possess the skills to capitalize on the opportunity that CIED reuse presents.

(3). Collaborate with regulatory agencies to create
more efﬁcient regulatory expectations to bring the
concept to scale
Signiﬁcant progress has been made through a partnership
with FDA regulators, but this collaboration must meet the
challenge of bringing CIED reuse for export to scale. While
the current regulatory path was created with commendable
effort, future endeavors must be streamlined. The newly
formed task force should establish relationships with regulators to ensure safe and effective updated regulatory expectations in North America and Europe around CIED exportation
for reuse. This process must require fewer resources, less
protocol, and fewer steps to build on prior success.

(4). Establishing a global CIED reuse registry for
quality assurance and future science
There are many potential beneﬁts of such a registry,
including maintaining high-quality standards for CIED reuse
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and providing feedback to the reprocessors, clinicians, and
regulators. The most recent study of CIED recycling employed a multinational prospective registry model developed
at the Montreal Heart Institute and a similar scalable solution
exists at University of Michigan MHYH. We propose an
ofﬁcial registry be modeled in a similar manner to help categorize, study, and improve clinical practices. While we
commend scientiﬁc efforts to date, the statistical power to understand and disseminate best practices, and to ensure quality
control as CIED recycling accelerates in volume, would be
more appropriate with a large registry, possibly in partnership
with international EP professional societies.
In summary, the health of a nation and its economic activity are inextricably linked. CIED recycling, primed to take
the next steps towards maturity, has the potential to make a
signiﬁcant impact on the leading cause of mortality in LMICs
worldwide. Not only is it medically feasible and ethical, but
the positive downstream effects on the economies of developing nations are as yet unmeasured and unrealized. We
encourage the global EP community to take these next steps
in advancing this international humanitarian practice in the
years ahead.
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